Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes

AE Cribb, DM Grant, MA Miller and SP Spielberg

Department of Pharmacology, University of Toronto, Ontario, Canada.

The expression of arylamine N-acetyltransferase (NAT) in leukocytes was investigated using p-aminobenzoic acid (PABA) and sulfamethazine (SMZ), substrates which are preferentially acetylated by the monomorphic NAT1 and polymorphic NAT2 enzymes, respectively. Activity towards both substrates was detected in mononuclear leukocytes (MNL; preparation containing approximately 80% lymphocytes), monocytes and neutrophils. PABA and SMZ acetylation rates were highly correlated in each of the isolated cell types. The NAT in leukocytes displayed a much higher affinity and turnover rate for the acetylation of PABA than for SMZ. These kinetic characteristics suggest that the acetylating activity in human leukocytes is predominantly attributable to the monomorphic enzyme NAT1. Neutrophils showed evidence of biphasic kinetics for SMZ which would indicate the coexpression of NAT1 and low levels of the polymorphic enzyme, NAT2. NAT activity in MNL was not influenced by the acetylator phenotype of the individual. There was, however, a significant correlation between NAT activity in MNL and the in vivo acetylation (urinary metabolite ratio) of p-aminosalicylic acid, which is monomorphically acetylated in humans. The expression of NAT1 in leukocytes and the virtuall absence of NAT2 may have important toxicological implications. The in vitro/in vivo correlation suggests that leukocytes may be a useful marker of systemic NAT1 activity.

Volume 259, Issue 3, pp. 1241-1246, 12/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				P. Meisel, J. Giebel, M. Peters, K. Foerster, I. Cascorbi, K. Wulff, J. Fanghaenel, and Th. Kocher Expression of N-acetyltransferases in Periodontal Granulation Tissue J. Dent. Res., May 1, 2002; 81(5): 349 - 353. [Abstract] [Full Text] [PDF]

				M. Payton, A. Mushtaq, T.-W. Yu, L.-J. Wu, J. Sinclair, and E. Sim Eubacterial arylamine N-acetyltransferases - identification and comparison of 18 members of the protein family with conserved active site cysteine, histidine and aspartate residues Microbiology, May 1, 2001; 147(5): 1137 - 1147. [Abstract] [Full Text]

				E. Sim, M. Payton, M. Noble, and R. Minchin An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes Hum. Mol. Genet., October 1, 2000; 9(16): 2435 - 2441. [Abstract] [Full Text] [PDF]

				J. H. de León, K. P. Vatsis, and W. W. Weber Characterization of Naturally Occurring and Recombinant Human N-Acetyltransferase Variants Encoded by NAT1* Mol. Pharmacol., August 1, 2000; 58(2): 288 - 299. [Abstract] [Full Text]

				R. S. King, C. H. Teitel, and F. F. Kadlubar In vitro bioactivation of N-hydroxy-2-amino-{alpha}-carboline Carcinogenesis, July 1, 2000; 21(7): 1347 - 1354. [Abstract] [Full Text] [PDF]

				M. Krajinovic, C. Richer, H. Sinnett, D. Labuda, and D. Sinnett Genetic Polymorphisms of N-Acetyltransferases 1 and 2 and Gene-Gene Interaction in the Susceptibility to Childhood Acute Lymphoblastic Leukemia Cancer Epidemiol. Biomarkers Prev., June 1, 2000; 9(6): 557 - 562. [Abstract] [Full Text]

				V. A. Smelt, A. Upton, J. Adjaye, M. A. Payton, S. Boukouvala, N. Johnson, H. J. Mardon, and E. Sim Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos Hum. Mol. Genet., April 12, 2000; 9(7): 1101 - 1107. [Abstract] [Full Text] [PDF]

				K. F. Windmill, A. Gaedigk, P. de la M. Hall, H. Samaratunga, D. M. Grant, and M. E. McManus Localization of N-Acetyltransferases NAT1 and NAT2 in Human Tissues Toxicol. Sci., March 1, 2000; 54(1): 19 - 29. [Abstract] [Full Text] [PDF]

				L. E. Adams and A.-B. Mongey Role of Genetic Factors in Drug-Related Autoimmunity Lupus, December 1, 1994; 3(6): 443 - 447. [Abstract] [PDF]